Profile data is unavailable for this security.
About the company
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
- Revenue in EUR (TTM)68.97m
- Net income in EUR-20.76m
- Incorporated1999
- Employees235.00
- LocationInnate Pharma SA117 avenue de Luminy, Bp 30191MARSEILLE 13009FranceFRA
- Phone+33 430303030
- Fax+33 430303000
- Websitehttp://www.innate-pharma.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abivax SA | -2.00k | -22.75m | 274.03m | 25.00 | -- | 15.42 | -- | -- | -2.21 | -2.21 | -0.0002 | 1.46 | -0.00004 | -- | -- | -- | -45.21 | -- | -61.90 | -- | -- | -- | -- | -- | -- | -24.32 | 0.5928 | -- | -- | -- | -93.39 | -- | -- | -- |
| Valneva SE | 126.56m | -7.83m | 338.68m | 508.00 | -- | 2.57 | -- | 2.68 | -0.087 | -0.087 | 1.41 | 1.45 | 0.4865 | 1.94 | 7.96 | 249,131.90 | -3.01 | -6.95 | -3.50 | -8.42 | 60.63 | 55.42 | -6.18 | -15.43 | 2.54 | -2.45 | 0.4272 | -- | 11.64 | 27.87 | -153.43 | -- | 23.83 | -- |
| AB Science SA | 1.57m | -21.75m | 378.02m | 103.00 | -- | -- | -- | 240.63 | -0.5573 | -0.5573 | 0.0399 | -0.645 | 0.0781 | 0.9452 | 7.26 | 15,252.43 | -108.11 | -76.90 | -2,891.89 | -171.18 | 88.48 | 84.76 | -1,384.28 | -1,469.31 | 0.7095 | -1,344.15 | -- | -- | -7.64 | -5.63 | 16.55 | -- | -10.07 | -- |
| Guerbet SA | 816.91m | 37.33m | 415.04m | 2.82k | 11.18 | 1.06 | 4.32 | 0.5081 | 2.95 | 2.95 | 64.50 | 31.01 | 0.7819 | 1.72 | 5.71 | 289,683.00 | 3.57 | 4.22 | 5.24 | 6.15 | 45.40 | 50.31 | 4.57 | 5.40 | 1.29 | 207.81 | 0.4926 | 24.60 | 3.46 | 14.84 | -20.27 | 7.40 | 13.97 | 6.96 |
| Innate Pharma SA | 68.97m | -20.76m | 446.56m | 235.00 | -- | 2.05 | -- | 6.47 | -0.2869 | -0.2869 | 1.03 | 2.76 | 0.1618 | -- | 25.85 | 293,506.40 | -4.87 | -3.91 | -7.77 | -5.64 | 95.35 | 93.44 | -30.10 | -23.54 | -- | -- | 0.1555 | -- | -13.67 | 137.80 | -780.85 | -- | 94.61 | -- |
| DBV Technologies SA | 13.14m | -153.59m | 448.76m | 311.00 | -- | 2.24 | -- | 34.15 | -4.22 | -4.22 | 0.355 | 3.65 | 0.0636 | 0.5394 | 1.21 | 42,247.59 | -74.34 | -53.84 | -95.51 | -61.88 | 92.60 | 90.07 | -1,168.93 | -1,142.63 | 3.75 | -113.04 | 0.1176 | -- | -9.62 | 22.51 | 7.52 | -- | 38.76 | -- |
| Boiron SA | 557.12m | 40.63m | 576.37m | 3.50k | 14.16 | 1.14 | 7.32 | 1.03 | 2.32 | 2.32 | 31.81 | 28.87 | 0.7276 | 1.78 | 5.40 | 159,087.10 | 5.30 | 8.78 | 6.61 | 11.11 | 77.16 | 78.87 | 7.28 | 10.92 | 2.47 | -- | 0.0251 | 41.22 | -7.79 | -1.79 | -29.29 | -14.52 | 10.24 | -6.89 |
| Vetoquinol SA | 395.99m | 28.59m | 651.13m | 2.13k | 22.68 | 1.68 | 15.55 | 1.64 | 2.42 | 2.42 | 33.47 | 32.65 | 0.8106 | 2.67 | 4.83 | -- | 5.78 | 6.81 | 7.05 | 8.45 | 47.99 | 57.52 | 7.13 | 8.39 | 1.94 | 387.07 | 0.0148 | 16.88 | 7.62 | 4.66 | -21.15 | 2.10 | 5.06 | -0.5182 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 07 May 2020 | 643.48k | 0.82% |
| Wellington Management Co. LLPas of 31 Dec 2019 | 359.94k | 0.46% |
| Schroder Investment Management Ltd.as of 31 Mar 2020 | 341.52k | 0.43% |
| HSBC Global Asset Management (France) SAas of 31 Jan 2020 | 320.87k | 0.41% |
| Sycomore Asset Management SAas of 30 Apr 2020 | 306.96k | 0.39% |
| TIAA-CREF Investment Management LLCas of 31 Mar 2020 | 286.31k | 0.36% |
| Goldman Sachs Asset Management LPas of 08 May 2020 | 274.32k | 0.35% |
| OFI Asset Management SAas of 31 Jan 2019 | 254.22k | 0.32% |
| Medical Strategy GmbHas of 31 Mar 2020 | 248.37k | 0.32% |
| La Fran�aise Asset Management SASas of 31 Jan 2020 | 200.00k | 0.25% |
